NASDAQ:YMABY-mAbs Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $38.03 -1.72 (-4.33 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$37.55Now: $38.03▼$40.9850-Day Range$35.13MA: $41.36▼$49.5352-Week Range$14.16Now: $38.03▼$50.49Volume141,277 shsAverage Volume173,407 shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/ABeta1.22 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 2.4 Analyst's Opinion Consensus RatingY-mAbs Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.17, Y-mAbs Therapeutics has a potential upside of 16.1% from its current price of $38.03.Amount of Analyst CoverageY-mAbs Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesY-mAbs Therapeutics has received 79 “outperform” votes. (Add your “outperform” vote.)Underperform VotesY-mAbs Therapeutics has received 84 “underperform” votes. (Add your “underperform” vote.)Community SentimentY-mAbs Therapeutics has received 51.53% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Y-mAbs Therapeutics and other stocks. Vote “Outperform” if you believe YMAB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe YMAB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,059,667.00 in company stock.Percentage Held by Insiders38.40% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.43% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($2.67) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -15.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -15.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:YMAB Previous Symbol CUSIPN/A CIKN/A Webwww.ymabs.com Phone646-885-8505Debt Debt-to-Equity Ratio0.01 Current Ratio12.79 Quick Ratio12.79Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.01 per share Price / Book7.59Profitability EPS (Most Recent Fiscal Year)($2.30) Net Income$-81,030,000.00 Net MarginsN/A Return on Equity-64.21% Return on Assets-57.03%Miscellaneous Employees32 Outstanding Shares39,760,000Market Cap$1.51 billion Next Earnings DateN/A OptionableNot Optionable $38.03 -1.72 (-4.33 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive YMAB News and Ratings via Email Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions How has Y-mAbs Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, YMAB stock has increased by 65.5% and is now trading at $38.03. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Y-mAbs Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Y-mAbs Therapeutics. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) issued its quarterly earnings data on Friday, August, 7th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.32. View Y-mAbs Therapeutics' earnings history. What price target have analysts set for YMAB? 8 analysts have issued 1 year price targets for Y-mAbs Therapeutics' stock. Their forecasts range from $39.00 to $52.00. On average, they expect Y-mAbs Therapeutics' stock price to reach $44.17 in the next year. This suggests a possible upside of 16.1% from the stock's current price. View analysts' price targets for Y-mAbs Therapeutics. Has Y-mAbs Therapeutics been receiving favorable news coverage? News stories about YMAB stock have been trending very positive on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Y-mAbs Therapeutics earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Y-mAbs Therapeutics. Who are some of Y-mAbs Therapeutics' key competitors? Some companies that are related to Y-mAbs Therapeutics include Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Zai Lab (ZLAB), Schrodinger (SDGR), Legend Biotech (LEGN), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), HYPERA S A/S (HYPMY) and Allakos (ALLK). View all competitors. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO) and ImmunoGen (IMGN). Who are Y-mAbs Therapeutics' key executives? Y-mAbs Therapeutics' management team includes the following people: Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. (Age 48)Dr. Claus Juan Møller San Pedro, CEO & Director (Age 56)Mr. Bo Kruse, Exec. VP, Sec., Treasurer, CFO & Director (Age 47)Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 44)Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 68) When did Y-mAbs Therapeutics IPO? (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager. What is Y-mAbs Therapeutics' stock symbol? Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB." Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (0.42%), New York State Common Retirement Fund (0.32%), Alps Advisors Inc. (0.14%), Swiss National Bank (0.11%), Vident Investment Advisory LLC (0.08%) and Vident Investment Advisory LLC (0.08%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, Bo Kruse, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Moller San Pedro Claus Juan, Pedro Claus Juan Moller-San and Thomas Gad. View institutional ownership trends for Y-mAbs Therapeutics. Which institutional investors are selling Y-mAbs Therapeutics stock? YMAB stock was sold by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, Vident Investment Advisory LLC, Strs Ohio, and Virtus ETF Advisers LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Bo Kruse, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, and Thomas Gad. View insider buying and selling activity for Y-mAbs Therapeutics. Which institutional investors are buying Y-mAbs Therapeutics stock? YMAB stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alps Advisors Inc., Bessemer Group Inc., Principal Financial Group Inc., ProShare Advisors LLC, State Board of Administration of Florida Retirement System, Rafferty Asset Management LLC, and New York State Common Retirement Fund. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy, Moller San Pedro Claus Juan, and Pedro Claus Juan Moller-San. View insider buying and selling activity for Y-mAbs Therapeutics. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Y-mAbs Therapeutics' stock price today? One share of YMAB stock can currently be purchased for approximately $38.03. How big of a company is Y-mAbs Therapeutics? Y-mAbs Therapeutics has a market capitalization of $1.51 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe. What is Y-mAbs Therapeutics' official website? The official website for Y-mAbs Therapeutics is www.ymabs.com. How can I contact Y-mAbs Therapeutics? Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
